Search results for "Growth hormone deficiency"

showing 10 items of 30 documents

MRI findings and genotype analysis in patients with childhood onset growth hormone deficiency--correlation with severity of hypopituitarism.

2007

Aim: To evaluate the relationship between pituitary size, PIT1 and PROP1 genotype, and the severity of childhood onset growth hormone deficiency (coGHD). Patients: Forty-four patients with coGHD (34 M; 9.7 ± 4.1 years): severe isolated (SI) GHD (n = 14); partial isolated (PI) GHD (n = 13); multiple pituitary hormone deficiencies (MPHD) (n=17). Results: Pituitary abnormalities were found in 7/14 patients with SIGHD (50%), 16/17 patients with MPHD (94.1%), and no patient with PIGHD. Mean pituitary height (PHT SDS) was significantly lower in MPHD than in SIGHD and PIGHD. Pituitary height SDS and pituitary volume (PV) SDS correlated with IGF-I SDS and stimulated GH peaks in the SIGHD and MPHD g…

Malemedicine.medical_specialtyAdolescentGenotypeEndocrinology Diabetes and MetabolismGenotype AnalysisHypopituitarismHypopituitarismGrowth hormone deficiencyCorrelationEndocrinologyInternal medicineAge Determination by SkeletonGenotypemedicineHumansIn patientAge of OnsetChildDwarfism PituitaryRetrospective StudiesHomeodomain Proteinsbusiness.industrymedicine.diseaseMagnetic Resonance ImagingBody HeightEndocrinologyChild PreschoolPituitary GlandPediatrics Perinatology and Child HealthPituitary hormonesDisease ProgressionFemalebusinessTranscription Factor Pit-1Mri findingsJournal of pediatric endocrinologymetabolism : JPEM
researchProduct

High prevalence of hypovitaminosis D in Sicilian children affected by growth hormone deficiency and its improvement after 12 months of replacement tr…

2014

PURPOSE: Although the correlation between vitamin D and growth hormone (GH)-insulin-like growth factor 1 (IGF1) axis is documented, as of date, few and conflicting studies have prospectively analyzed vitamin D before and after GH treatment. Our aim was to evaluate as to how the condition of GH deficiency (GHD) or GH treatment influences vitamin D in children. METHODS: Eighty Sicilian GHD children (M/F 58/22; mean age 10.3 years), grouped according to the season of evaluation in group A (June-September; 41 children) and group B (November-February; 39 children), were evaluated at baseline and after 12 months of GH treatment. RESULTS: Twenty-eight children (35 %) were vitamin D insufficient an…

Malemedicine.medical_specialtyAdolescentHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentComorbidityGrowth hormoneGrowth hormone deficiencySettore MED/13 - EndocrinologiaYoung AdultEndocrinologyHypovitaminosisInternal medicinemedicineVitamin D and neurologyPrevalenceHumansChildDwarfism Pituitaryvitamin D growth hormoneHigh prevalencebusiness.industryHuman Growth HormoneGrowth factorInfantmedicine.diseaseVitamin D DeficiencyEndocrinologyTreatment OutcomeChild PreschoolGh treatmentFemalebusinessGH Deficiency
researchProduct

Improvement of treatment adherence with growth hormone by easypod™ device: experience of an Italian centre

2018

Abstract Background One of the most important vulnerabilities falling the efficacy of recombinant human growth hormone (r-hGH) treatment is low adherence especially in young patients. This study was planned to describe the correlation between r-hGH treatment efficacy and adherence in real-life setting using easypod™. Methods Forty patients younger than 18 years, affected by a clinical condition in which r-hGH is available and treated with r-hGH easypod™, were enrolled in a retrospective, observational, real-world data, monocentric trial. The study design provided the retrospective collection of records collected by a questionnaire proposed to the patients and their parents and compared with…

Malemedicine.medical_specialtyAdolescentTreatment adherenceInjections SubcutaneousTurner syndrome030209 endocrinology & metabolismSelf AdministrationInjections SubcutaneouGrowth hormone deficiencyMedication Adherence03 medical and health sciencesEasypod™0302 clinical medicinePatient satisfactionDrug Delivery SystemsGrowth DisorderRetrospective StudieInternal medicineTurner syndromemedicineHumansTreatment adherence030212 general & internal medicineChildGrowth DisordersRetrospective StudiesR-hGHbusiness.industryHuman Growth HormoneResearchlcsh:RJ1-570Retrospective cohort studylcsh:PediatricsSmall for gestational ageRecombinant Proteinmedicine.diseaseRecombinant ProteinsPatient SatisfactionChild PreschoolPediatrics Perinatology and Child HealthSmall for gestational ageObservational studyFemaleGrowth hormone deficiencybusinessSelf-administrationDrug Delivery SystemHumanItalian Journal of Pediatrics
researchProduct

Correlation between adrenal function, growth hormone secretion, and insulin sensitivity in children with idiopathic growth hormone deficiency

2017

Purpose Patients with growth hormone deficiency (GHD) demonstrate an increased cortisol/cortisone ratio which could potentially explain the metabolic features of GHD, while GH treatment (GHT) could increase the cortisol metabolism. Methods In 35 children (27 M, mean age 10.1 years) with idiopathic GHD at baseline and after 12 months of GHT and in 25 controls, in addition to metabolic parameters, we assessed adrenal function by morning serum cortisol, its peak, and its area under the curve (AUCCOR) during insulin tolerance test (ITT). Results A cortisol peak <18 µg/dl was shown in 22 and 31% of GHD children at baseline and after GHT, respectively. At baseline, GHD children had lower fasting …

Malemedicine.medical_specialtyGHD adrenal insufficiencyCortisol awakening responseHydrocortisoneEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismSettore MED/13 - EndocrinologiaGrowth hormone deficiency03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceInternal medicineAdrenal GlandsmedicineHumansProspective Studies030212 general & internal medicineChildDwarfism PituitaryMorningHydrocortisoneHuman Growth Hormonebusiness.industryInsulin tolerance testPrognosismedicine.diseaseGrowth hormone secretionEndocrinologyCase-Control StudiesChild PreschoolFemaleAdrenal Cortex Function TestsInsulin ResistanceCortisonebusinessBiomarkershormones hormone substitutes and hormone antagonistsFollow-Up Studiesmedicine.drugJournal of Endocrinological Investigation
researchProduct

Comparison between euglycemic hyperinsulinemic clamp and surrogate indices of insulin sensitivity in children with growth hormone deficiency

2018

Objective: Data about the impact of growth hormone treatment (GHT) on insulin sensitivity in children are quite controversial, due to the different surrogate indices that have been used. Design: We evaluated insulin sensitivity through the euglycemic hyperinsulinemic clamp, considered the gold standard technique, in 23 children affected by growth hormone deficiency (GHD) at baseline and after 12. months of GHT and in 12 controls with short stature at baseline, and we compared the clamp-derived index (M-value) with the most commonly used surrogate index of insulin sensitivity, as ISI Matsuda, and with circulating plasma markers of insulin sensitivity, as adiponectin and resistin levels. Resu…

Malemedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismShort statureGrowth hormone deficiencySettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineGlucose IntolerancemedicineHumansResistinProspective StudiesChildGrowth DisordersEuglycemic hyperinsulinemic clampAdiponectinHuman Growth Hormonebusiness.industryGrowth hormone deficiency; Hyperinsulinemic clamp; Insulin sensitivity; Endocrinology Diabetes and Metabolism; EndocrinologyInsulin sensitivityHyperinsulinemic clampGold standard (test)Glucose Tolerance TestPrognosismedicine.diseaseInsulin sensitivityGrowth hormone treatmentEndocrinologyCase-Control Studies030220 oncology & carcinogenesisGlucose Clamp TechniqueFemaleResistinGrowth hormone deficiencyAdiponectinInsulin Resistancemedicine.symptombusinessBiomarkersFollow-Up Studies
researchProduct

Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly propose…

2015

Purpose To evaluate the clinical and metabolic behavior of children with isolated growth hormone (GH)-deficiency (GHD), grouped according to the new AIFA criteria for the appropriateness of use and reimbursement of GH treatment in children. Methods The clinical and metabolic data of 310 prepubertal children (220 M, 90 F; mean age 10.8 years) grouped, according to new AIFA note 39, into group A (No 181 with a peak of GH 10 µg/L) were retrospectively analyzed. Group A and B, diagnosed as having GHD, were treated with GH for at least 24 months, while group C was analyzed only at baseline. Results At baseline, group A showed higher waist circumference than B (p=0.031) and C (p=0.041), while no …

Malemedicine.medical_specialtyWaistAdolescentEndocrinology Diabetes and Metabolismmedicine.medical_treatmentGroup AGroup BGrowth hormone deficiencySettore MED/13 - Endocrinologiachemistry.chemical_compoundGovernment AgenciesEndocrinologyInternal medicineOutcome Assessment Health CaremedicineHumansChildDwarfism PituitaryGrowth hormone childrenbusiness.industryCholesterolInsulinmedicine.diseaseEndocrinologyItalychemistryChild PreschoolGrowth HormoneConcomitantPractice Guidelines as TopicGh treatmentFemalebusinessFollow-Up Studies
researchProduct

Prolactin secretion before, during, and after chronic gonadotropin-releasing hormone agonist treatments in children.

2005

Objective To examine the effect of long-term administration of GnRH agonists (GnRHa) on PRL secretion in children affected by central precocious puberty (CPP) and growth hormone deficiency (GHD). Design Prospective analysis of blood sampling before, during, and after GnRHa treatments. Setting Pediatric endocrine center. Patient(s) One hundred nineteen and 93 children with a diagnosis of CPP and GHD, respectively. Intervention(s) Monthly depot injections of GnRHa drugs (leuprorelin acetate 3.75 mg [LA] and triptorelin 3.75 mg [TR]) administered to CPP and GHD patients for 40 and 24 months, respectively. Main Outcome Measure(s) Serum PRL levels at baseline and after 6, 12, 18, 24, 30, 36, and…

Malemedicine.medical_specialtymedicine.drug_classPuberty PrecociousGonadotropin-releasing hormoneGrowth hormone deficiencyGonadotropin-Releasing HormoneLeuprorelinInternal medicineGonadotropin-releasing hormone agonistmedicinePrecocious pubertyHumansProspective StudiesChildbusiness.industryHuman Growth HormoneObstetrics and Gynecologymedicine.diseaseTriptorelinProlactinProlactinEndocrinologyReproductive MedicineChild PreschoolFemalebusinessBlood samplingmedicine.drugFertility and sterility
researchProduct

Appropriate management of growth hormone deficiency during the age of transition: an Italian Delphi consensus statement

2022

Growth hormone deficiency (GHD) describes the impairment of growth hormone (GH) secretion by the pituitary somatotroph cells. GHD may be congenital, with causes, including genetic alterations and structural brain malformations, or acquired, including midline tumours, cranial irradiation, traumatic brain injury, central nervous system infections and inflammatory conditions. GHD in children is characterised by short stature, delayed bone maturation and abnormalities in substrate metabolism, body composition, physical and psychosocial functioning, all of which improve with recombinant human GH (rhGH) therapy. The diagnosis of GHD is based on clinical signs and symptoms, biochemistry and imagin…

growth hormone deficiencySettore MED/38 - Pediatria Generale E SpecialisticaEndocrinologyage of transitionconsensusItalian Delphi consensus statementEndocrinology Diabetes and Metabolismadolescentgrowth hormone; transition; consensusgrowth hormonetransitionTransition agegrowth hormone deficiency; Transition age; adolescent
researchProduct

Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency

2003

Summary objective Little is known of the usefulness of GH secretagogues (GHSs) in GH-deficient (GHD) adults. The objective of this study was to determine the number of responders to treatment with NN703 in GHD adults. design A multicentre, randomized, double-blind, and placebo-controlled study. patients Ninety-seven GHD adults were included. measurements The GH response before and after 1 week of oral treatment with NN703 (n = 83) or placebo (n = 14) was determined. The first and last dose of NN703 was 3 mg/kg, whereas the dose of NN703 was 1·5 mg/kg/day during the 6 days between the first and last doses. Furthermore, all 97 patients received 1 µg/kg GH-releasing hormone (GHRH) 3 weeks afte…

medicine.medical_specialtyChemotherapybusiness.industryEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPlacebomedicine.diseaseGrowth hormone deficiencyEndocrinologyBlood pressureEndocrinologyOral administrationGrowth hormone secretagogueInternal medicineStatistical significancemedicinebusinessHormoneClinical Endocrinology
researchProduct

Glucose Metabolism in Children With Growth Hormone Deficiency

2018

Background: The growth hormone (GH)/insulin-like growth factor 1 (IGF-1) axis has a fundamental impact on glucose metabolism. Therefore, both untreated GH deficiency (GHD) and GH treatment (GHT) may be associated with some metabolic alterations, although the abnormalities of glucose metabolism have been investigated by relatively few studies as main outcomes. Aim: The present review summarizes the available data on glucose metabolism in children with GHD, providing an overview of the current state of the art in order better to clarify the real metabolic impact of GHD and GHT. Methods: Among all the existing studies, we evaluated all original studies that fulfilled our criteria for analysis …

medicine.medical_specialtyChildren; Glucose; Growth hormone; Insulin sensitivity; Metabolism; Endocrinology Diabetes and MetabolismEndocrinology Diabetes and MetabolismMini Review030209 endocrinology & metabolismCarbohydrate metabolismGrowth hormonelcsh:Diseases of the endocrine glands. Clinical endocrinologyReporting parametersGrowth hormone deficiencySettore MED/13 - EndocrinologiaFasting glucose03 medical and health sciences0302 clinical medicineInsulin resistanceEndocrinologychildrenInternal medicinemedicineGlucose homeostasisinsulin sensitivityglucoselcsh:RC648-665business.industryMetabolismmedicine.diseaseEndocrinology030220 oncology & carcinogenesisgrowth hormonebusinessmetabolismFrontiers in Endocrinology
researchProduct